Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
adenocarcinoma

- Histologic documentation of the original primary tumor is required via pathology
report

- FIGO stage III-IV disease

- Must have received 5-8 courses of front-line taxane- and platinum-based chemotherapy
OR treatment on a first-line Gynecologic Oncology Group (GOG) protocol AND must have
become clinically free of disease as measured by serum CA-125 level, CT scan, or
physical examination

- Must have documentation of a defined progression-free interval after front-line
therapy, as measured from the date of initiation of front-line chemotherapy to
the date of initiation of second-line chemotherapy

- Relapsed disease (prior to starting second-line chemotherapy), defined by 1 of the
following:

- Doubling of serum CA-125 level confirmed by measurements taken 1 week apart

- CA-125 level should have been elevated to at least double the level seen
during the first complete response

- Identification of a new lesion by CT/MRI scan or physical examination

- Must have completed 5-8 courses of second-line taxane- and platinum-based
chemotherapy 4-8 weeks ago

- Second-line chemotherapy must not have been started before clear evidence of
disease recurrence was documented using RECIST criteria

- Achieved complete clinical response to second-line chemotherapy with no symptoms
suggestive of persistent disease, defined by the following:

- Normal physical examination

- Reduction from the peak serum CA-125 level to a normal value of ≥ 5 U/mL

- Complete regression of recurrent lesions by CT scan of the abdomen/pelvis

- No low malignant potential tumors or noninvasive disease

PATIENT CHARACTERISTICS:

- GOG performance status 0-1

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 8.0 g/dL

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- AST ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- No active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus
erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, or ankylosing
spondylitis)

- No known allergy to murine proteins, documented anaphylactic reaction to any drug, or
intolerance to cyclophosphamide

- No recognized immunodeficiency disease, including cellular immunodeficiencies,
hypogammaglobulinemia, or dysgammaglobulinemia

- No acquired, hereditary, or congenital immunodeficiencies

- No other concurrent uncontrolled diseases

- No contraindications to pressor agents

- No other invasive malignancies within the past 5 years, except nonmelanoma skin
cancer

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior cancer treatment that would contraindicate study therapy

- No concurrent chronic treatment with immunosuppressive drugs (e.g., cyclosporine,
adrenocorticotropic hormone [ACTH], or systemic corticosteroids)